Ho et al. suggested that Chinese or Japanese ancestry may be related to developing neuropsychiatric adverse events of oseltamivir. However, this is unlikely, since no clinically relevant differences in the plasma pharmacokinetics of oseltamivir and its active metabolite oseltamivir carboxylate have been noted between Japanese and Caucasian adults or children (6). Moreover, there is evidence to suggest that neuropsychiatric adverse events in Japanese children with influenza occurred before starting oseltamivir, and these events were similar to those occurring after treatment. This is consistent with previous findings that influenza itself is associated with higher risk of neuropsychiatric events. Analysis of medical records in the United Kingdom General Practice Research Database showed significantly higher adjusted relative risk (1.75) of such symptoms in influenza patients than in the general population, an analysis performed when antivirals were seldom used (6). Therefore, general practitioners and psychiatrists should be watchful for psychiatric complications following influenza and other viral infections, particularly in predisposed individuals.